Trial: Tropion-Pantumor01

TROPION-PanTumor01: datopotamab deruxtecan in advanced HER2+ breast cancer

TROPION-Lung01 & TROPION-Lung05: datopotamab deruxtecan for NSCLC

PROs from TROPION-Breast01: datopotamab deruxtecan in HR+/HER2- breast cancer

Efficacy of datopotamab deruxtecan, a TROP2 ADC, in aNSCLC

Highlights on datopotamab deruxtecan in advanced NSCLC: The TROPION-Lung01 study

European Society for Medical Oncology (ESMO)

TROPION-PanTumor03: datopotamab deruxtecan in advanced solid tumors

BEGONIA: datopotamab deruxtecan and durvalumab in metastatic triple-negative breast cancer

Ongoing studies for datopotamab deruxtecan in NSCLC

Breast Cancer Breakthroughs: TROPION-Breast02 Trial

Susan G. Komen®

Biopsy analyses from the TALAVE trial of induction talazoparib

Dr Bazhenova on Updated Data From the TRUST-I Trial of Taletrectinib in ROS1+ NSCLC

#ESMO21 Expert Video Report on novelties in metastatic NSCLC

European Society for Medical Oncology (ESMO)

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Oncology

Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast Cancer

Targeted Oncology

Antibody Drug Conjugates for Cancer

Antibody-drug conjugates for the treatment of breast cancer

Phase II trial of patritumab deruxtecan in metastatic breast cancer

Single-cell spatial analysis in TNBC from NeoTRIPaPDL1

The APHINITY Trial in Early-Stage HER2+ Breast Cancer

Targeted Oncology

Interim results from DESTINY-Lung01: T-DXd in HER2-overexpressing NSCLC